메뉴 건너뛰기

대메뉴 건너뛰기 대메뉴 바로가기

Events

go to homeHOME  >  NEWS & EVENTS  >  EVENTS
[Seminar Notification] Dr. Inho Jo_05.19.2016
2016-05-12

1. Title : Tonsil-derived stem cells: A potential application to parathyorid regeneration

2. Speaker : Inho Jo, Ph.D.

3. Affiliation : Professor and Chairman, Department of Molecular Medicine, Ewha Womans University School of Medicine

4. Date : 05. 19. 2016 16:00-17:00

5. Place : SIMS Main Building, Auditorium 109 (1F)

6. Abstract :

Parathyroid cells release parathyroid hormone (PTH), which controls calcium homeostasis. Loss of parathyroid cells results in hypoparathyroidism and consequent low-turnover bone disease. Here, we investigated whether our recently-established human tonsil-derived mesenchymal stem cells (TMSC) restore in vivo parathyroid cell function in rats with parathyroidectomy (PTX). Compared with undifferentiated control TMSC, TMSC differentiated with activin A and soluble sonic hedgehog induced a significant release of PTH as early as day 7, with increased PTH release occurring in response to lower calcium levels and vice versa. Released PTH increased osteocalcin expression and alizarin red S staining in preosteoblastic cells, indicating its functional activity. PTX rats fed calcium-free diet only survived for ~10 days. Subcutaneous injection with TMSC alone did not increase their survival rates, regardless of differentiation. However, survival rates increased for up to 1 month in response to TMSC embedded in Matrigel (TMSC-MA), showing 40% and 80% in control and differentiated TMSC-MA, respectively. When compared with continuous increases by control TMSC-MA, stable levels of secreted PTH and serum ionized calcium were found in PTX rats with differentiated TMSC-MA. Although this data suggest that differentiated TMSC resemble parathyroid cells and, if embedded in Matrigel, restore in vivo parathyroid function, we need to establish more clinically-applicable parathyroid regeneration system because of a little biocompatibility of Matrigel. Most recently, we newly-developed a scaffold-free spheroidal construct of differentiated TMSC, showing higher survival rates (~50%) over 3 month periods, with physiological levels of both serum PTH and ionized calcium. This is the first report that a scaffold-free spheroidal construct of differentiated TMSC is likely to be clinically-feasible strategy for hypoparathyroidism treatment.